FindTrial
Sign In

GLAD

A 4-week, phase-II, double-blind, placebo-controlled, randomized, parallel group, multi-centre study to assess the efficacy and tolerability/safety of inhaled AZD3199 once daily compared to 9mcg formoterol bid and placebo in patients with moderate to severe COPD

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220766
Enrollment
Unknown
Registered
2009-07-06
Start date
2009-07-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

investigational material(s) Generic name etc : AZD3199 INN of investigational material : Therapeutic category code : 225 Bronchodilators Dosage and Administration for Investigational material : Dry p

Sponsors

AstraZeneca
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - COPD - Current or exsmokers, at least 10 pack years

Exclusion criteria

Exclusion criteria: - Asthma - Any clinically relevant abnormal findings at screenin examinations - Recent COPD exacerbation

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026